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Abstract
Background: Bluetongue virus (BTV) and African horse sickness virus (AHSV) are distinct arthropod borne virus
species in the genus Orbivirus (Reoviridae family), causing the notifiable diseases Bluetongue and African horse
sickness of ruminants and equids, respectively. Reverse genetics systems for these orbiviruses with their ten-segmented
genome of double stranded RNA have been developed. Initially, two subsequent transfections of in vitro synthesized
capped run-off RNA transcripts resulted in the recovery of BTV. Reverse genetics has been improved by transfection of
expression plasmids followed by transfection of ten RNA transcripts. Recovery of AHSV was further improved by use of
expression plasmids containing optimized open reading frames.
Results: Plasmids containing full length cDNA of the 10 genome segments for T7 promoter-driven production of full
length run-off RNA transcripts and expression plasmids with optimized open reading frames (ORFs) were used. BTV and
AHSV were rescued using reverse genetics. The requirement of each expression plasmid and capping of RNA
transcripts for reverse genetics were studied and compared for BTV and AHSV.
BTV was recovered by transfection of VP1 and NS2 expression plasmids followed by transfection of a set of
ten capped RNAs. VP3 expression plasmid was also required if uncapped RNAs were transfected. Recovery of AHSV
required transfection of VP1, VP3 and NS2 expression plasmids followed by transfection of capped RNA
transcripts. Plasmid-driven expression of VP4, 6 and 7 was also needed when uncapped RNA transcripts were
used. Irrespective of capping of RNA transcripts, NS1 expression plasmid was not needed for recovery, although NS1
protein is essential for virus propagation. Improvement of reverse genetics for AHSV was clearly demonstrated by
rescue of several mutants and reassortants that were not rescued with previous methods.
Conclusions: A limited number of expression plasmids is required for rescue of BTV or AHSV using reverse genetics,
making the system much more versatile and generally applicable. Optimization of reverse genetics enlarge
the possibilities to rescue virus mutants and reassortants, and will greatly benefit the control of these
important diseases of livestock and companion animals.
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Background
Bluetongue (BT), African horse sickness (AHS), and
epizootic haemorrhagic disease (EHD) are OIE listed
arthropod borne animal diseases caused by the viruses
in the genus Orbivirus, family Reoviridae. These viruses
are spread by specific species of Culicoides biting
midges. Outbreaks and geographic expansion of affected
areas are associated to various factors, including climate
change [1, 2], and the presence of competent biting
Culicoides midges [3]. Culicoides species in countries
with a moderate climate are competent insect vectors
for BTV [4–6]. This implies that countries historically
free of disease are probably at risk for BT and other
midge borne diseases [7].
The prototype bluetongue virus (BTV) and African
horse sickness virus (AHSV) are the best studied orbi-
viruses, reviewed in [8]. Orbiviruses are non-enveloped
virus particles consisting of the subcore protein VP3,
surrounded by serogroup specific protein VP7 (core),
and the outer shell of the particle is formed by serotype
specific protein VP2 and VP5. Orbiviruses contain a
ten-segmented double stranded (ds) RNA genome
(Seg-1–10). Replication proteins VP1, VP4 and VP6
are present in the virus particle [8]. In addition to
structural proteins VP1-7, at least four non-structural
proteins NS1 - 4 are expressed after infection of
mammalian and insect cells but these are not present
in the infectious virus particle.
After cell entry, the orbivirus particle is uncoated by
removing VP2 and VP5 resulting in a transcription-
active core particle that synthesizes capped messenger
RNAs (mRNAs) of each genome segment. In addition to
translation, these mRNAs act as template for dsRNA
synthesis after recruitment from the cytoplasm into nas-
cent virus particles. Together with replication proteins
VP1, 4 and 6, and VP3, replication complexes are
formed in virus inclusion bodies, and synthesize dsRNA
in subcore particles which become core particles by
addition of VP7 and virions by assembly of outer shell
proteins VP2 and VP5. NS1 protein enhances protein
expression from viral mRNAs [9]. NS2 recruits mRNA
from the cytoplasm and is involved in the formation of
VIBs [10]. NS3/NS3a is cytotoxic in mammalian cells
but more prominent in insect cells, and is involved in
non-lytic virus release from in particular insect cells
[11, 12]. BTV NS3/NS3a also suppresses interferon
induction in mammalian cells [13]. NS4 proteins of
orbiviruses also seems to interfere with the host immune
response and are important for virulence [14–18]. Re-
cently, an additional protein expressed by Seg-10 has been
discovered the functions of which are still unclear [19].
For a long time, research on orbiviruses has been ham-
pered by the lack of reverse genetics systems. Functional
studies on orbivirus proteins in infected cells were
limited to natural variability in proteins and reassortants.
First, one or two genome segments in BTV were re-
placed by incorporation of in vitro run-off RNA tran-
scripts [20, 21]. Now, reverse genetics (RG) has been
developed for different genera of the Reoviridae family,
including for BTV and AHSV [22–25]. Recovery of reas-
sortants showed that the constellation of the BTV gen-
ome is flexible [23, 26–31]. RG has also been used to
study viral proteins [11, 14], as well as the role of RNA
sequences in virus replication [32–35].
RG has also been used to develop very promising
novel vaccines for orbiviruses. Disabled Infectious
Single Cycle/Cell (DISC) vaccine or in-trans comple-
mented BTV lacks the gene encoding essential VP6,
but can be rescued and produced in constitutively VP6
expressing cells [36]. Disabled Infectious Single Animal
(DISA) vaccine lacks the gene encoding non-essential
NS3/NS3a which includes the DIVA principle [37],
and has been produced in well-known cell lines simi-
lar to these for live-attenuated BT vaccines [11, 38].
Both novel BT vaccines have been explored for differ-
ent serotypes by exchange of serotype determining
genome segments using RG [39, 40]. Similarly, prom-
ising AHS DISA vaccine candidates has been devel-
oped using RG [12].
RG based on exclusively plasmids for in vivo run-off
RNA transcripts has been developed recently for BTV
[41]. Further, RG systems based on exclusively in vitro
synthesized capped run-off RNA transcripts were modi-
fied by use of protein expression from plasmids for initial
protein synthesis [24, 42]. Obviously, reverse genetics
for orbiviruses is now used in functional studies as well
as for vaccine development and the methods have
changed over time. Here, we studied and compared the
requirements to recover BTV and AHSV using reverse
genetics in more detail.
Methods
Cell lines and viruses
BSR cells (a clone of baby hamster kidney cells [43])
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; Invitrogen) containing 5 % foetal bovine serum
(FBS), 100 IU/ml penicillin, 100 μg/ml streptomycin and
2.5 ug/ml Amphotericin B. Live-attenuated AHSV4LP
has been generated approximately 50 years ago by differ-
ent passages and plaque purification. The official passage
number is HS32/62—10S-10BHK-3LP-7Vero [44]. BTV6/
net08 is closely related to live-attenuated BT vaccine for
serotype 6 [45, 46]. Reverse genetics of BTV6/net08 and
AHSV4LP has been published [12, 26]. Virus stocks were
obtained by infection of fresh BSR cells with a multiplicity
of infection (MOI) of 0.1, and stored at 4 °C or -80 °C.
Virus titres were determined by endpoint dilution and
expressed as 10log TCID50/ml.
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Full length cDNA of genome segments
Full genome segment sequences of BTV6/net08 and
AHSV4LP have been described (accession numbers:
QG506472-QG506481 and accession numbers:
KM820849-KM820858, respectively) [12, 26]. cDNAs
of Seg-10[NS3/NS3a] of AHSV2 and AHSV3 have been de-
scribed (accession numbers: KF860005 and KM886363).
cDNAs of Seg-2[VP2] and Seg-6[VP5] of other AHSV
serotypes have been described [12, 27, 40].
Full genome segments were synthesized by Genscript
corporation (Piscataway NJ, USA) and cDNAs were
cloned in appropriate plasmids under control of the T7
promoter and 3’-terminally flanked by a restriction en-
zyme site suitable for full length run-off RNA transcrip-
tion (Fig. 1a) [12, 23, 26]. Alternatively, internal sites of
restriction enzymes were eliminated by synonymous mu-
tations to allow full length run-off transcription, and
expression of unchanged proteins. Mutated cDNAs of
several genome segments were synthetically derived or
constructed by standard procedures and have been de-
scribed previously [12], except for Seg-10 ‘AUG total’
containing AUG- > GCC mutations for all 13 AUG co-
dons of the NS3/NS3a ORF. delSeg-5 of AHSV contains
an out-of-frame deletion of 79 nucleotides (nucleotide
position 286-364). All plasmids were transformed and
maintained in E. coli strain DH5α (Invitrogen) and were
isolated using the High Pure Plasmid Isolation Kit
(Roche) or the QIAfilter Plasmid Midi Kit (Qiagen). T7
RNA-polymerase driven run-off transcription was per-
formed for capped RNAs with the mMESSAGE mMA-
CHINE® T7 Ultra Kit, and for uncapped RNAs with the
MEGAscript® T7 Kit as described [26]. Synthesized RNAs
were purified using the MEGAclear kit (Ambion) accord-
ing to manufacturer’s protocol and stored at -80 °C.
Expression plasmids
Authentic open reading frames (ORF) of VP1, 3, 4, 6, 7,
NS1 and 2 of AHSV4LP were inserted in expression
plasmid HC pSMART or LC pSMART under control of
the immediate early promoter of human cytomegalo-
virus by standard procedures (Fig. 1b) [47]. Plasmid with
ORF-VP3 of AHSV4LP was unstable. A similar set of ex-
pression plasmids including for ORF-VP3 was constructed
with the respective ORF optimized for eukaryotic ex-
pression and plasmid stability (Genscript corporation,
Piscataway NJ, USA). Similarly, a set of expression plas-
mids with optimized ORF of VP1, 3, 4, 6, NS1 and 2 of
BTV6/net08 was constructed. Expression plasmids were
transformed and maintained as described for plasmids
with full segment cDNAs.
Immunoperoxidase monolayer assay (IPMA)
Protein expression was determined by immunoperoxi-
dase monolayer assay (IPMA) according to standard
procedures [48]. Transfected or infected monolayers of
BSR cells were fixed with methanol/aceton (1:1) or 4 %
paraformaldehyde in PBS. Immunostaining was per-
formed by incubation with orbivirus directed antibodies
followed by conjugated rabbit α-mouse serum or conju-
gated rabbit α-GP serum (DAKO). Monoclonal antibody
(MAb) against BTV-VP7 (ATCC-1875) was used to de-
tect BTV transfected/infected cells. For AHSV, MAb
10AE12 directed against VP5 and several MAbs were
used directed against AHSV-NS3 (generous gifts from
Paloma Rueda, Ingenasa, Spain). Guinea pig (GP) sera
raised against baculovirus expressed VP2 protein (α-VP2
GP serum) of different AHSV serotypes have been
published [49].
Virus recovery from in vitro synthesized RNA transcripts
Reverse genetics (RG) using exclusively in vitro synthe-
sized RNAs has been described for BTV [23, 26]. Briefly,
monolayers of 105 BSR cells per 2 cm2 were transfected
twice with 600 ng RNA containing equimolar amounts
of capped run-off RNA transcripts of six segments
followed by transfection with a set of all 10 RNA tran-
scripts. After 4 h, transfection medium was replaced by
culture medium, and after 2 days culture medium was
a
b
Fig. 1 Schematic presentation of plasmids for run-off RNA transcription and protein expression. a cDNA of full genome segments were cloned
between the promoter for DNA dependent RNA polymerase of bacteriophage T7 (PT7) and a recognition site of restriction enzyme (RE) SapI, BsmBI, or
BsaI to allow run-off RNA transcription. The appropriate RE was selected based on the absence of the recognition sites in the respective genome
segment. Alternatively, internal sites were eliminated by silent mutations with respect to the translated amino acid sequence. b Authentic or open
reading frames (ORFs) optimized for plasmid stability and eukaryotic expression (see materials and methods) were cloned between the
immediate early promoter of human cytomegalovirus (PHCMV) and the polyA signal (polyA) and transcription terminator (TER)
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harvested. Virus recovery was determined by infection
of fresh BSR monolayers. Cytopathogenic effect (CPE)
and the immunoperoxidase monolayer assay (IPMA)
confirmed virus recovery and virus identity. If negative,
duplicate transfected wells were passed, screened for
CPE and immunostained as described above. Sequential
passaging of cells was repeated was repeated with immu-
nostaining serving as indicator of virus replication. If
immunostaining was no longer visible, attempts were
repeated at least twice in order to conclude that virus
recovery was considered unsuccessful.
Virus recovery using expression plasmids and RNA
transcripts
Reverse genetics (RG) using expression plasmids and in
vitro synthesized RNAs is very similar to the method
using exclusively in vitro synthesized RNAs [12, 26].
Briefly, BSR monolayers in 2 cm2 wells were first trans-
fected with equimolar amounts of expression plasmids
followed by transfection of the set of 10 RNAs as de-
scribed above. A total of 600 or 300 ng DNA plasmids
was transfected using 1.5 or 0.75 μl Lipofectamine™ 2000
(1:2.5; 1 mg/ml, Invitrogen) in Opti-MEM® I Reduced
Serum Medium according to manufacturer’s conditions.
The transfection of 10 RNAs was carried out as de-
scribed above. For AHSV, the RNA transfection was the
same but transfection medium was replaced after 22 h,
and transfected monolayers were passed once. Medium
was harvested after 2 days to infect fresh monolayers in
order to confirm virus recovery. If negative, duplicate
wells with transfected cells were processed as described
for recovery of BTV.
Recovery of virus mutants and reassortants
Mutants and reassortants of BTV and AHSV were gen-
erated according to the described and indicated methods
(Table 1). Mutations and replaced genome segments
were confirmed by sequencing as previously described
[11, 12]. Briefly, entire Seg-10 was amplified using
primers located at the ultimate ends followed by sequen-
cing. Seg-2 and Seg-6 were partially amplified with
appropriate primers and amplicons were sequenced.
Consensus sequences were assembled for complete Seg-
10 using Lasergene SeqMan Pro Software (DNASTAR,
version 11) to verify the identity of introduced muta-
tions. The identity of Seg-2 and Seg-6 was confirmed by
alignment of the partially derived sequences.
Plaque morphology (CPE) was determined as previously
described [11, 12]. Briefly, BSR monolayers were infected
at a multiplicity of infection (MOI) of 0.1. After incubation
of infected monolayers under overlay medium (K1000
complete with 1 % methylcellulose), cells were fixed with
methanol/aceton (1:1) and immunostained. Cytopatho-
genic effect (CPE) of separate plaques were compared,
and semi-quantitated as normal (+), small or no CPE (-).
Expression of proteins was studied by IPMA with MAbs
or α-VP2 directed GP sera as described [12].
Results
Reverse genetics of AHSV4LP
Initially, recovery of AHSV4LP by transfecting in vitro
synthesized capped run-off RNA transcripts on two
subsequent days was studied according to reverse gen-
etics (RG) method for BTV [26]. Unfortunately, ‘syn-
thetic’ AHSV4LP could not be recovered (not shown).
Briefly, the level of protein expression was studied after
transfection of AHSV-VP7 capped RNA transcript. VP7
expression was also investigated by IPMA after transfec-
tion of capped run-off RNA transcripts of Seg-1[VP1],
Seg-3[VP3], Seg-4[VP4], Seg-5[NS1], Seg-8[NS2], Seg-
9[VP6], and Seg-7[VP7]. Transient expression and
replication-driven enhancement of VP7 expression were
expected, but immunostaining was hardly observed (not
shown), suggesting that expression from capped run-off
AHSV-RNA transcripts was too weak to initiate replica-
tion of AHSV.
Expression plasmids for ORFs of VP1, 3, 4, 6, 7, and
NS1 and 2 were constructed to increase and to extend
protein expression. However, the plasmid with VP3-ORF
was not stable, and the ORF was successfully optimized
for plasmid stability and eukaryotic expression. Results
with VP7 expression plasmid showed a stronger expres-
sion compared to that from capped RNA (not shown).
Transfection of expression plasmids of VP1, 3, 4, 6, 7, and
NS1 and 2 followed by transfection of 10 in vitro synthe-
sized capped run-off RNA transcripts resulted in recovery
of AHSV4LP (Table 2). Apparently, the high expression
from plasmids contributed to recovery of AHSV4LP.
Requirements for recovery of AHSV4LP
AHSV4LP was recovered with six expression plasmids
containing authentic ORFs and optimized ORF for VP3,
whereas recovery without VP7 expression plasmid was
not successful. In contrast, NS1 expression plasmid was
not required (Table 2). Lowering the amount of plasmids
from 600 to 300 ng did not abolish recovery, while the
damage to the monolayer by transfection was reduced.
This shows the benefits of using plasmids with high
protein expression levels.
Virus recovery using expression plasmids with opti-
mized ORFs was studied (Table 2). Apparently, opti-
mized ORFs encode functional proteins as AHSV4LP
was recovered. Now, the contribution of individual ex-
pression plasmids in virus recovery was investigated.
Plasmid-driven expressions of VP4, VP6, VP7, and NS1
was not essential for virus recovery using capped RNAs
in the second transfection (Table 2). Note that plasmid-
driven VP7 expression was essential for virus recovery
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with non-optimized ORFs in expression plasmids. Ex-
pression plasmids for VP1, VP3, and NS2 are essential
for virus recovery. Indeed, transfection of these three ex-
pression plasmids followed by transfection of 10 capped
RNA transcripts resulted in virus recovery (Table 2).
However, all expression plasmids including VP7 were
required in combination with transfection of uncapped
RNA transcripts, except for NS1 expression plasmid. Re-
garding NS1 protein, virus recovery was not successful
without entire Seg-5 RNA or with mutated Seg-5 lacking
functional NS1 expression (Table 2). We conclude that
Seg-5 RNA and the expressed NS1 protein are essential
for AHSV replication, but are not required to initiate
virus recovery in transfected cells.
Requirements for recovery of BTV6/net08
Previously, RG for BTV using exclusively in vitro synthe-
sized capped run-off RNA transcripts, have resulted in
reassortants, mutants and variants with spontaneously
introduced changes during rescue [27, 40]; [11, 33]. On
the other hand, several modifications appeared not vi-
able [32, 35, 40]. Here, expression plasmids with opti-
mized ORFs of VP1, 3, 4, 6, and NS1 and 2 of BTV6/
net08 were successfully used (Table 3). However, the
improved RG method with expression plasmids did not
result in rescue of previous nonviable BTV mutants (not
shown). Subsequent studies showed that plasmid-driven
expression of VP3, 4, 6 and NS1 are not required. This
was confirmed by transfection of VP1 and NS2
Table 1 Overview of rescued AHSV4LP variants demonstrating the improvements of the RG method
Name Seg of AHSV4LP1 Segment exchange2 600 ng 300 ng 300 ng Virus rescue CPE3 VP5 IPMA4
a b c VP2 NS3
AHSV4LP 1–10 - + + + + + 4 +
Serotyped 3 1, 3–5, 7–10 (2, 6) 3 - + nd + + 3 nd
Serotyped 6 1, 3–5, 7–10 (2/6) 6 - + nd + + 6 nd
AHSV1LP 1, 3–10 (2) 1 nd + nd + + 1 nd
AHSV2LP 1, 3–10 (2) 2 - + nd + + 2 nd
AHSV3LP 1, 3–10 (2) 3 - + nd + + 3 nd
AHSV4LP 1–10 - + + + + + 4 +
AHSV5LP 1, 3–10 (2) 5 - - + + + 5 nd
AHSV6LP 1, 3–10 (2) 6 - + nd + + 6 nd
AHSV7LP 1, 3–10 (2) 7 nd + nd + + 7 nd
AHSV8LP 1, 3–10 (2) 8 nd + nd + + 8 nd
AHSV9LP 1, 3–10 (2) 9 nd + nd + + 9 nd
AHSV4LP 1–10 - + + + + + 4 +
Without Seg-10 1–9 - - - - - - nd nd
Seg-10 of AHSV2 1–9 (10) 2 nd nd + + + nd +
Seg-10 of AHSV3 1–9 (10) 3 - - + + + nd +
mutAUG1 1–9 (10) AUG1 + nd nd + + nd +
mutAUG1 + 2 1–9 (10) AUG1 + 2 nd + nd + Small nd +
mutAUG1 + 2 & STOPS 1–9 (10) AUG1 + 2&STOPS nd + nd + Small nd +
delLD 1–9 (10) delLD - + nd + Small nd +
delTMR1 1–9 (10) delTMR1 nd nd + + - nd -
delTMR2 1–9 (10) delTMR2 nd nd + + - nd ±
AUG total 1–9 (10) AUGtotal nd nd + + - nd -
AHSV1LP + (mutAUG1 + 2 & STOPS) 1, 3–9 (2) 1, (10) AUG1 + 2&STOPS nd - + + Small 1 +
AHSV8LP + (mutAUG1 + 2 & STOPS) 1, 3–9 (2) 8, (10) AUG1 + 2&STOPS nd + + + Small 8 +
AHSV8LP + (AUG total) 1, 3–9 (2) 8, (10) AUGtotal nd nd + + - 8 -
(1) In total, a mixture of 600 or 300 ng in equal molar amounts of seven expression plasmids were transfected followed by transfection of indicated RNAs of Seg-1
to 10. (2) Exchanged Seg-2[VP2] or Seg-10[NS3/NS3a] are indicated. AHSV1LP to AHSV9LP and all Seg-10 mutants have been described previously, except for
Seg-10 ‘AUG total’ containing AUG- > GCC mutations for all 13 AUG codons of the NS3/NS3a ORF. Expression plasmids contained authentic ORFs, except
for ORF-VP3 (a & b), or all seven expression plasmids with ORFs optimized for plasmid stability and eukaryotic expression (c). In total, 600 or 300 ng expression
plasmids were used. Virus rescue was determined and confirmed by IPMA and indicated as successful (+), unsuccessful (-), or not done (nd). (3) After immunostaining
with α-VP5 MAb, plaque morphology was microscopically scored as normal CPE (+), small CPE (small), or immunostained plaques without CPE (-). (4) IPMA results with
the respective α-VP2 GP serum is indicated by the serotype number, and with α-NS3 MAbs as positive (+), weak (±), negative (-) or not done (nd)
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expression plasmids and subsequent transfection of 10
capped run-off RNA transcripts. In combination with
uncapped RNA transcripts, however, VP3 expression
plasmid was also required for BTV recovery (Table 3).
Note that the requirement of expression plasmids for
BTV recovery in combination with uncapped RNA tran-
scripts is similar to the requirement of expression plas-
mids for AHSV recovery in combination with capped
RNAs, namely VP1, VP3 and NS2 expression plasmids.
Improved reverse genetics for AHSV demonstrated by
rescue of mutants and reassortants
AHSV4LP was not recovered with RG using exclusively
RNAs, whereas many mutants and reassortants were
generated with expression plasmids followed by RNA
transfection (Table 1). Throughout this study, the initial
RG method for AHSV was slightly modified by lowering
the amount of plasmids from 600 to 300 ng, and by
using optimized AHSV-ORFs in expression plasmids.
Many more virus variants were rescued with modified
RG methods, indicating that these modifications obvi-
ously improved the method. For example, exchange of
both Seg-2 and Seg-6 of serotypes 3 and 6 in AHSV4LP
was initially not successful, whereas after lowering the
amount of expression plasmid these were rescued. Simi-
larly, single Seg-2 exchange of serotype 2, 3, and 6, and
incorporation of delLD in AHSV4LP were rescued with
this improved method (Table 1). Single exchange of Seg-
10 of AHSV3 and Seg-2 of serotype 5 were only rescued
by use of expression plasmids with optimized ORFs
(Table 1). Many more mutants, reassortants and combi-
nations of these were rescued with this method, since
the suboptimal methods were no longer used (nd,
Table 1). In practical terms, these results demonstrated
the clear improvements of the RG method to regenerate
AHSV variants.
Taken together, a set of nine single Seg-2 reassortants
AHSV1LP – AHSV9LP was rescued as promising AHS
vaccine candidates [12]. Further, a set of three Seg-10
reassortants representing three phylogenetic lineages of
Seg-10 was rescued [50, 51]. Finally, we showed that
NS3/NS3a knockout mutations can be combined with
Table 3 Requirements of expression plasmids and run-off RNA
transcripts for BTV recovery
Expression plasmids with optimized ORFs RNA Virus
VP1 VP3 VP4 VP6 NS1 NS2 Transcripts Recovery
- - - - - - Capped -
+ + + + + + Capped +
- + + + + + Capped -
+ - + + + + Capped +
+ + - + + + Capped +
+ + + - + + Capped +
+ + + + - + Capped +
+ + + + + - Capped -
+ - - - - + Capped +
+ + + + + + Uncapped +
+ - + + + + Uncapped -
+ + - + + + Uncapped +
+ + + - + + Uncapped +
+ + + + - + Uncapped +
+ - - - - + Uncapped -
+ + - - - + Uncapped -
BTV expression plasmids with optimized ORFs in the first transfection mix are
indicated. Then, monolayers were transfected with 10 full length in vitro
synthesized capped or uncapped run-off RNA transcripts. Virus recovery
was microscopically determined by CPE and confirmed by IPMA, and indicated
as positive (+) or negative (-)
Table 2 Requirements of expression plasmids and run-off RNA
transcripts for AHSV recovery
Expression plasmids with authentic ORFs RNA Virus
VP1 VP3 VP4 VP6 VP7 NS1 NS2 Transcripts Recovery
- - - - - - - Capped -
+ + + + + + + Capped +
+ + + + - + + Capped -
+ + + + + - + Capped +
Expression plasmids with optimized ORFs RNA Virus
VP1 VP3 VP4 VP6 VP7 NS1 NS2 Transcripts Recovery
+ + + + + + + Capped +
- + + + + + + Capped -
+ - + + + + + Capped -
+ + - + + + + Capped +
+ + + - + + + Capped +
+ + + + - + + Capped +
+ + + + + - + Capped +
+ + + + + + - Capped -
+ + - - - - + Capped +
+ + + + + + + Uncapped +
+ + - + + + + Uncapped -
+ + + - + + + Uncapped -
+ + + + - + + Uncapped -
+ + + + + - + Uncapped +
+ + - - - - + Uncapped -
+ + + + + + + minSeg-5 -
+ + + + + + + delSeg-5 -
AHSV expression plasmids in the first transfection mix are indicated. In the
upper panel, non-optimized ORFs in expression plasmids were used, except
for ORF-VP3. In the lower panels, expression plasmids with optimized AHSV-ORFs
were used. Then, monolayers were transfected with 10 full length in vitro
synthesized capped or uncapped run-off RNA transcripts, except for minSeg-5
RNA (without) and delSeg-5 RNA (Seg-5 RNA with a small out-of-frame deletion).
Virus recovery was microscopically determined by CPE and confirmed by IPMA,
and indicated as positive (+) or negative (-)
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exchange of genome segments, like for Seg-2 represent-
ing the serotype of AHSV.
Discussion
Reverse genetics (RG) has been developed for viruses of
many families including those with double stranded
RNA (dsRNA) segmented genomes. The latter includes
members of Birnaviridae [52, 53], and different genera
within the Reoviridae family [25]. RG for BTV, the
prototype member of the Orbivirus genus has also been
developed. This RG method followed two subsequent
transfections of in vitro synthesized positive single
stranded capped run-off RNA transcripts [23]. Capped
RNAs expressing VP1, 3, 4, 6, and NS1 and NS2 were
used for primary protein expression followed by trans-
fection of a set of ten uncapped RNA transcripts to re-
cover BTV containing these genome segments [26].
However, a similar RG system for AHSV was not suc-
cessful [12]. These results indicate that recovery of BTV
is more efficient than for AHSV.
Primary protein expression by the first transfection of
RNA transcripts can be replaced by plasmid-driven ex-
pression for BTV recovery [42]. A similar method was
also successful for AHSV [12, 24]. Apparently, RG by
plasmid-driven expression followed by RNA transfection
is more efficient than by transfection of exclusively RNA
transcripts. Further, increase of the primary protein ex-
pression changes the amount of plasmids critical for
AHSV recovery. Use of optimized-ORF expression plas-
mids, excludes the need of VP7 by which the require-
ments for RG of AHSV becomes similar to that of BTV
(Tables 2 and 3).
NS1 expression by the first transfection is not essential
for recovery of BTV and AHSV (Tables 2 and 3) [42]. NS1
increases protein synthesis from BTV RNAs [9], which ex-
plains that NS1 expression is not required for virus recov-
ery with plasmid-driven protein expression. Expectedly,
Seg-5 and its expressed NS1 protein of AHSV are essential
for AHSV replication, since AHSV without Seg-5 or with
mutated Seg-5 abolishing NS1 expression were not res-
cued (Table 2). In further agreement to BTV, initial VP7
expression is not required for AHSV recovery (Tables 2
and 3). AHSV-VP7 is however essential for RG with au-
thentic ORF expression plasmids (Table 2). Others have
suggested that VP7 stabilizes the BTV replication complex
[42]. Similarly, it can be suggested that AHSV-VP7 is
beneficial for AHSV recovery by stabilizing the replication
complex as observed with suboptimal conditions, like the
lower AHSV protein expression from authentic ORFs
compared to optimized ORFs. These results indicate that
initial NS1 and VP7 expression are not essential, but bene-
ficial for virus recovery.
The minimal requirements of plasmid-driven expres-
sion differs between BTV and AHSV (Tables 2 and 3).
VP1 and NS2 expression plasmids are essential for re-
covery of BTV and AHSV, irrespective of capped RNAs
in the second transfection. VP3 expression plasmid is
also essential, although BTV was recovered without VP3
expression plasmid in combination with capped RNA
transcripts. Apparently, expression of VP1, VP3 and NS2
is essential for recovery of both orbiviruses, although de-
layed and lower expression of VP3 is sufficient for recov-
ery of BTV.
Similar to the enhancement in recovery by VP7, we
suggest that VP3 enhances orbivirus recovery by in-
crease of the initial replication activity by stabilization of
premature replication complexes and the formation of
subcore particles. Consequently, suboptimal expression
of VP1 and NS2 requires expression of VP3 and VP7 to
efficiently recovery virus. In full agreement with this, in
vitro reconstitution of infectious BTV core particles
showed that VP1, VP4 and VP6 form a transcription
complex that does not need other proteins for its activity
[54]. NS2 recruits mRNA from the cytoplasm to the rep-
lication complex and forms virus inclusion bodies in
vivo [10], and is therefore not needed for in vitro recon-
stitution of core particles.
Small amounts of VP4, 6 and 7 expressed from capped
RNAs after 18–22 h are sufficient to initiate recovery of
AHSV. These capped RNA transcripts are not needed
for BTV recovery (Tables 2 and 3). Others have shown
that VP6 is essential for BTV replication and acts early
in the replication cycle of BTV [55]. We suggest that
very low expression levels of these proteins from either
uncapped RNA or after in vivo capping of transfected
uncapped RNA transcripts are sufficient to initiate BTV
recovery in our system. We have noticed that not all at-
tempts with these conditions were successful suggesting
that the efficiency of virus recovery was much lower.
Summarizing, VP1 and NS2 expression plasmids are
essential for an optimized RG system of BTV and AHSV.
VP3 expression plasmid is also essential for BTV recov-
ery if uncapped RNAs are used. In contrast, only NS1
expression plasmid could be omitted in combination
with uncapped RNAs for AHSV recovery. Generally, we
conclude that recovery of BTV is more efficient than of
AHSV. In order to increase the success rate for rescue
of mutants and reassortants, the most optimal system is
the combination of all seven expression plasmids with
optimized ORFs and capped RNA transcripts for the
second transfection. BTV1 and BTV8 variants were gen-
erated using BTV6 based ORF-optimized expression
plasmids [35], and virulent AHSV5 was similarly recov-
ered with AHSV4LP based expression plasmids (pub-
lished elsewhere). We propose that one set of expression
plasmids of the respective orbivirus species in combin-
ation with a set of ten even uncapped run-off RNA tran-
scripts will be sufficient to quickly recover new orbivirus
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variants. A reproducible and efficient RG system is a pre-
requisite to conclude the lethality of mutations or genome
constellations. Still, the essentiality of viral proteins or le-
thality of mutations could be conclusively demonstrated
by use of in trans complementation followed by virus pas-
sage on ordinary cells [55].
Requirements for RG of BTV and AHSV showed many
similarities as well as differences, likely caused by the
difference in efficiency of virus recovery, but fundamen-
tal differences between these orbivirus species cannot be
excluded. This comparative analysis of reverse genetics
for orbivirus prototypes BTV and AHSV will contribute
to development of RG methods for other orbiviruses,
such as the OIE listed, notifiable epizootic haemorrhagic
disease virus, but also for other orbiviruses and reoviruses.
This will increase our understanding of the complex repli-
cation cycle and assembly process of these viruses with a
segmented double stranded RNA genome.
Conclusions
For optimal function of RG systems for the rescue of
BTV and AHSV, a limited number of expression plasmids
is required. Optimization of reverse genetics enlarge the
possibilities to rescue virus mutants and reassortants.
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